Skip to content

Cohort study, 2017

Are oxidation levels abnormal in women with PMDD?

No. Women with PMDD did not differ from healthy controls in oxidant-antioxidant balance or paraoxonase-1 enzyme levels, despite having higher depression and anxiety symptoms.

Moderate study design 20 women with PMDD and 30 healthy controls, assessed across 2 menstrual cycles

What they did

A follow-up cohort study measured serum hormone (estrogen, progesterone), oxidant, antioxidant, and paraoxonase-1 levels in 20 women with PMDD and 30 healthy controls during both follicular and luteal phases of two consecutive menstrual cycles. Depression, anxiety, and sleep were also assessed using standard rating scales.

What they found

No significant differences between groups in estrogen, progesterone, total oxidant-antioxidant, or paraoxonase-1 levels or sleep quality. Women with PMDD had significantly higher depression and anxiety scores. Hormone and oxidant-antioxidant levels did not correlate with depression, anxiety, or sleep scores.

What it means for you

Standard measures of oxidative stress do not appear to be the primary problem in PMDD, despite higher mood symptoms. The findings suggest it may be more useful to assess cellular stress parameters longitudinally rather than as single measurements. However, this is a small study with only 20 women with PMDD.

20

women with PMDD

30

healthy controls

2

consecutive menstrual cycles assessed

About the study

Original title
Total oxidant–antioxidant and paraoxonase-1 levels in premenstrual dysphoric disorder: a follow-up study
Authors
Halil Özcan, Elif Oral, Mustafa Güleç et al.
Journal
Psychiatry and Clinical Psychopharmacology
Year
2017
Study design
Cohort study
Participants
50
Open access
Yes
Original abstract

Objective: Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS) that was categorized as a mood disorder in the most recent version of the Diagnostic and Statistical Manual for Mental Disorders. In addition to a history of PMS, a PMDD diagnosis requires prospective symptom assessment for 2 consecutive menstrual periods. Although the effects of some oxidants–antioxidants were previously studied in PMS, their possible effects in PMDD remain unknown. Paraoxonase-1 (PON-1) is a new high-density lipoprotein-associated enzyme with many antioxidative effects. We hypothesized that assessing serum total oxidant–antioxidant and PON-1 levels could clarify the role of oxidant–antioxidant system in PMDD.Methods: All participants (n = 50) were assessed by an experienced psychiatrist for PMDD by using the Diagnostic and Statistical Manual for Mental Disorders-IV (DSM-IV), Premenstrual Assessment Form and Daily Record of Severity of Problems (DRSP)-Short Form or possible psychiatric disorders including depression, anxiety, and sleep disorders. Serum estrogen, progesterone, total oxidant–antioxidant, and paraoxonase-1 (PON-1) levels were measured in the serum of 20 participants with PMDD and 30 asymptomatic controls during the follicular and luteal phases of two consecutive menstrual cycles. Sleep quality, depression, and anxiety symptoms were assessed with the Pittsburg Sleep Quality Index (PSQI), Hamilton Depression Rating Scale (HDRS), and Hamilton Anxiety Rating Scale (HARS), respectively.Results: There were no significant intergroup differences in estrogen, progesterone, oxidant–antioxidant, or PON-1 levels or PSQI scores. However, the mean HDRS and HARS scores were statistically significantly higher for patients with PMDD than for controls. Levels of estrogen, progesterone, and total oxidant–antioxidant were not correlated with HDRS, HARS, or PSQI scores.Conclusions: Considering the lack of differences in hormonal and biochemical levels between the two groups, it may be more efficient and discriminative to longitudinally assess biochemical and cellular stress-related parameters in subjects with PMDD.

Reproduced under CC-BY.

Topics